News
Hutchmed rises on $1.3bn KRAS licensing deal with GSK
GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.
R&D
Back to basics: X-ray inspection in pharmaceutical and medic...
In pharma manufacturing, x-ray inspection supports a range of quality control processes.
News
Akeso's ivonescimab extends survival in PD-L1+ lung cancer
Akeso's PD-1xVEGF drug ivonescimab improves survival in another late-stage Chinese trial, ahead of a key international study readout later this year.
News
Boehringer signs AI drug discovery deal with Owkin
Boehringer Ingelheim has joined Sanofi and AstraZeneca in signing up to deploy Owkin's AI platform K Pro in its drug discovery operations.
News
PMV cues up filing for first p53-directed cancer therapy
PMV is preparing to file for approval of its first-in-class oral p53 protein reactivator, rezatopopt, for ovarian cancer in the first quarter of 2027.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
